Insider Selling: Xencor, Inc. (NASDAQ:XNCR) VP Sells 68,684 Shares of Stock

Xencor, Inc. (NASDAQ:XNCR) VP John R. Desjarlais sold 68,684 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $23.48, for a total value of $1,612,700.32. Following the completion of the sale, the vice president now directly owns 200,104 shares in the company, valued at approximately $4,698,441.92. This represents a 25.55 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Xencor Trading Down 1.8 %

XNCR opened at $23.07 on Friday. Xencor, Inc. has a 1-year low of $15.31 and a 1-year high of $26.84. The firm has a 50-day moving average price of $21.12 and a two-hundred day moving average price of $20.40. The stock has a market capitalization of $1.61 billion, a PE ratio of -7.21 and a beta of 0.66. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.98) by $0.27. The firm had revenue of $10.70 million during the quarter, compared to analysts’ expectations of $14.59 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. Xencor’s revenue was down 81.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.40) EPS. As a group, equities analysts anticipate that Xencor, Inc. will post -3.79 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Xencor

Large investors have recently made changes to their positions in the company. Primecap Management Co. CA increased its position in Xencor by 0.3% in the second quarter. Primecap Management Co. CA now owns 9,116,202 shares of the biopharmaceutical company’s stock worth $172,570,000 after purchasing an additional 25,495 shares during the period. Vanguard Group Inc. grew its position in shares of Xencor by 3.6% during the 1st quarter. Vanguard Group Inc. now owns 7,011,042 shares of the biopharmaceutical company’s stock worth $155,154,000 after buying an additional 243,793 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Xencor by 9.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,819,656 shares of the biopharmaceutical company’s stock worth $84,530,000 after buying an additional 335,881 shares during the last quarter. Point72 Asset Management L.P. lifted its holdings in Xencor by 147.3% in the third quarter. Point72 Asset Management L.P. now owns 3,120,229 shares of the biopharmaceutical company’s stock valued at $62,748,000 after buying an additional 1,858,440 shares during the period. Finally, Logos Global Management LP boosted its stake in Xencor by 130.8% in the second quarter. Logos Global Management LP now owns 1,500,000 shares of the biopharmaceutical company’s stock valued at $28,395,000 after acquiring an additional 850,000 shares during the last quarter.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. BMO Capital Markets reissued an “outperform” rating and set a $34.00 price objective (up from $32.00) on shares of Xencor in a report on Friday, November 8th. Royal Bank of Canada lifted their price target on shares of Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a report on Thursday, September 26th. JPMorgan Chase & Co. upped their price objective on shares of Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Finally, Wedbush reiterated an “outperform” rating and issued a $38.00 target price on shares of Xencor in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $35.75.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.